(βR)-β-amino-Benzenepropanol 1-carbamate hydrochloride (1:1), known as Solanezumab, is a monoclonal antibody drug candidate developed by Eli Lilly and Company. Its chemical name refers to a key chiral intermediate or a structural motif related to its synthesis. Solanezumab is designed to target soluble amyloid-beta (Aβ) peptides in the brain, which are believed to play a central role in the progression of Alzheimer's disease. The primary application of Solanezumab is as a potential therapeutic agent for Alzheimer's disease. It functions by binding to soluble Aβ peptides, thereby preventing their aggregation into neurotoxic oligomers and plaques. This mechanism aims to slow cognitive decline by neutralizing the toxic species thought to drive neurodegeneration. Clinical trials have extensively investigated its efficacy in patients with mild Alzheimer's disease, though results regarding significant clinical benefit have been mixed. As a biopharmaceutical, Solanezumab represents a significant investment in neurodegenerative disease research. Its development underscores the focus on the amyloid hypothesis. The "(βR)" designation highlights the importance of chirality in its active structure or synthesis, which is critical for its biological activity and specificity.